Gene therapy for neuropathic pain induced by spared nerve injury with naked plasmid encoding hepatocyte growth factor

2017 ◽  
Vol 19 (12) ◽  
pp. e2994 ◽  
Author(s):  
Chunsheng Hu ◽  
Yuxin Lu ◽  
Xiaochen Cheng ◽  
Yufang Cui ◽  
Zuze Wu ◽  
...  
Keyword(s):  
Gene Therapy ◽  
Neuropathic Pain ◽  
Growth Factor ◽  
Hepatocyte Growth Factor ◽  
Nerve Injury ◽  
Spared Nerve Injury ◽  
Naked Plasmid ◽  
Hepatocyte Growth

Gene therapy for rat liver cirrhosis by naked hepatocyte growth factor gene transffer into liver

2000 ◽  
Vol 118 (4) ◽  
pp. A1014
Author(s):  
Masaharu Takeuchi ◽  
Hiranari Kanemura ◽  
Takahiro Ueki ◽  
Kiyoshi Horiguchi ◽  
Yasukane Asano ◽  
...  
Keyword(s):  
Gene Therapy ◽  
Liver Cirrhosis ◽  
Growth Factor ◽  
Hepatocyte Growth Factor ◽  
Rat Liver ◽  
Factor Gene ◽  
Growth Factor Gene ◽  
Hepatocyte Growth

scholarly journals Safety Evaluation of Clinical Gene Therapy Using Hepatocyte Growth Factor to Treat Peripheral Arterial Disease

Hypertension ◽  
2004 ◽  
Vol 44 (2) ◽  
pp. 203-209 ◽  
Author(s):  
Ryuichi Morishita ◽  
Motokuni Aoki ◽  
Naotaka Hashiya ◽  
Hirofumi Makino ◽  
Keita Yamasaki ◽  
...  
Keyword(s):  
Gene Therapy ◽  
Growth Factor ◽  
Peripheral Arterial Disease ◽  
Hepatocyte Growth Factor ◽  
Safety Evaluation ◽  
Arterial Disease ◽  
Clinical Gene Therapy ◽  
Peripheral Arterial ◽  
Hepatocyte Growth

Neonatal or hepatocyte growth factor–potentiated adult gene therapy with a retroviral vector results in therapeutic levels of canine factor IX for hemophilia B

Blood ◽  
2003 ◽  
Vol 101 (10) ◽  
pp. 3924-3932 ◽  
Author(s):  
Lingfei Xu ◽  
Cuihua Gao ◽  
Mark S. Sands ◽  
Shi-Rong Cai ◽  
Timothy C. Nichols ◽  
...  
Keyword(s):  
Gene Therapy ◽  
Growth Factor ◽  
Gene Transfer ◽  
Hepatocyte Growth Factor ◽  
Retroviral Vector ◽  
Factor Ix ◽  
Hemophilia B ◽  
Hepatocyte Growth

AbstractHemophilia B is a bleeding disorder resulting from factor IX (FIX) deficiency that might be treated with gene therapy. Neonatal delivery would correct the disease sooner than would transfer into adults, and could reduce immunological responses. Neonatal mice were injected intravenously with a Moloney murine leukemia virus–based retroviral vector (RV) expressing canine FIX (cFIX). They achieved 150% to 280% of normal cFIX antigen levels in plasma (100% is 5 μg/mL), which was functional in vitro and in vivo. Three newborn hemophilia B dogs that were injected intravenously with RV achieved 12% to 36% of normal cFIX antigen levels, which improved coagulation tests. Only one mild bleed has occurred during 14 total months of evaluation. This is the first demonstration of prolonged expression after neonatal gene therapy for hemophilia B in mice or dogs. Most animals failed to make antibodies to cFIX, demonstrating that neonatal gene transfer may induce tolerance. Although hepatocytes from newborns replicate, those from adults do not. Adult mice therefore received hepatocyte growth factor to induce hepatocyte replication prior to intravenous injection of RV. This resulted in expression of 35% of normal cFIX antigen levels for 11 months, although all mice produced anti-cFIX antibodies. This is the first demonstration that high levels of FIX activity can be achieved with an RV in adults without a partial hepatectomy to induce hepatocyte replication. We conclude that RV-mediated hepatic gene therapy is effective for treating hemophilia B in mice and dogs, although the immune system may complicate gene transfer in adults.

scholarly journals Long-term effects of hepatocyte growth factor gene therapy in rat myocardial infarct model

Gene Therapy ◽  
2011 ◽  
Vol 19 (8) ◽  
pp. 836-843 ◽  
Author(s):  
Y-N Jin ◽  
M Inubushi ◽  
K Masamoto ◽  
K Odaka ◽  
I Aoki ◽  
...  
Keyword(s):  
Gene Therapy ◽  
Growth Factor ◽  
Hepatocyte Growth Factor ◽  
Myocardial Infarct ◽  
Long Term Effects ◽  
Factor Gene ◽  
Growth Factor Gene ◽  
Myocardial Infarct Model ◽  
Hepatocyte Growth
Sign in / Sign up

Export Citation Format

Share Document